IGEA calls extraordinary general meeting

Hoofddorp, the Netherlands, 22 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the convening of an extraordinary general meeting (the “EGM”) for Wednesday, 28 April 2021. The EGM will resolve on matters regarding the business combination with Blue Sky Natural Resources LTD (“BSNR”) as further indicated below (and as previously disclosed by IGEA on 8 August 2020 and 15 February 2021) and on the appointment of newly proposed non-executive directors.

Read More

IGEA announces changes in its board

Hoofddorp, the Netherlands, 4 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mr. Camillo Ricordi and Mr. Barth Armand Green from its board of directors for personal reasons.

Read More

IGEA to update on business combination

Hoofddorp, the Netherlands, 15 February 2021. IGEA Pharma N.V. (SIX: IGPH) today announced an update on the business combination with Blue Sky Natural Resources LTD (“BSNR”) disclosed for the first time on 8 August 2020.

Read More

IGEA ensures ‘Alz1’ supply for the EU market

Hoofddorp, the Netherlands, 6 December 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the signature of an agreement with CSM Europe for the ‘CE’ compliant supply of Alz1. The distribution of Alz1 on a wholesale basis in selected EU markets is expected to start within the first half of 2021.

Read More

IGEA announces changes in its board

Hoofddorp, the Netherlands, 21 October 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mr. Mark De Simone from the board of directors for professional reasons related to other executive activities.

Read More

IGEA and Blue Sky Natural Resources to combine businesses

Hoofddorp, the Netherlands, 8 August 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the signing of a letter of intent, binding upon the parties in terms, with Blue Sky Natural Resources LTD (“BSNR”), a privately held company specialized in transforming vegetable matrices into innovative and high tech value products for the health, nutraceutical and cosmeceutical industry, to combine the two companies’ businesses, subject to the approval by both companies’ respective general meetings and certain other closing conditions as detailed below. The transaction is structured through a contribution in-kind by the BSNR shareholders of at least 75% of the BSNR shares into IGEA by subscribing newly issued shares in a dedicated share capital increase of IGEA. The combination will create an EU headquartered and SIX-listed company with an innovative early-stage commercial and a strong development pipeline focusing on health prevention and nutraceutical solutions including hemp, ikuvia and other vegetable matrices extracts from CO2 supercritical technology.

Read More

IGEA announces changes in its board

Hoofddorp, the Netherlands, 7 August 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mr. Marco Seniga from its board of directors for personal reasons related to his retirement. Seniga also terminated his engagement with the company as director of marketing and
sales.

Read More

IGEA announces changes in its board

Hoofddorp, the Netherlands, 2 June 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the nomination of Mr. Lieven Baten for election as non-executive director of IGEA at the upcoming general meeting on 3 July 2020. Lieven Baten is a partner at Acalis, with which IGEA has previously signed a strategic partnership for the distribution of its products.

Read More